# Analysis of the clinical characteristics of direct oral anticoagulants-associated atraumatic splenic rupture

**Authors:** Can Shi, Xia Wang, Siyi Zhang, Ren Guo, Tian Wu

PMC · DOI: 10.3389/fphar.2026.1777780 · Frontiers in Pharmacology · 2026-03-06

## TL;DR

This study examines a rare but serious complication of direct oral anticoagulants (DOACs) called atraumatic splenic rupture, highlighting the importance of early diagnosis and treatment.

## Contribution

The study provides a detailed clinical analysis of DOAC-associated atraumatic splenic rupture cases, emphasizing risk factors and management strategies.

## Key findings

- Atraumatic splenic rupture occurred in 27 patients, most commonly associated with apixaban.
- Elderly patients with comorbidities and polypharmacy were at higher risk.
- Most patients survived with interventions like transfusion, embolization, and splenectomy.

## Abstract

Atraumatic splenic rupture (ASR), though rare, is an adverse event linked to direct oral anticoagulants (DOACs). Given their widespread use and potentially fatal consequences if undiagnosed, heightened clinical awareness of DOAC-associated ASR is crucial. Our aim was to analyze the occurrence and clinical characteristics of ASR induced by DOACs.

We conducted a retrospective analysis of all reported DOAC-associated ASR cases through 15 April 2025, without language restrictions.

A total of 27 patients (11 males and 16 females) were included with a median age of 64 years. Among them, apixaban (n = 17) was the most common DOAC, followed by rivaroxaban (n = 8) and dabigatran (n = 2), with atrial fibrillation (81.5%, n = 22) being the primary indication. The comorbidities observed among patients with DOAC-associated ASR risk included hypertension (25.9%), coronary heart disease (18.5%), malignancy (18.5%), and infections (18.5%). Among 27 patients, 11 (40.7%) received concomitant medications that may potentiate DOAC effects, with 5 patients taking four interacting drugs simultaneously. Only 4 of the 11 patients had documented anticoagulant dosages, half of which were full-dose regimens. Management included immediate DOAC cessation (100.0%), transfusion (77.8%), splenic artery embolization (44.4%), and splenectomy (70.4%) – with 31.6% of splenectomies representing salvage procedures following failed embolization. All patients were successfully discharged with no mortality.

ASR is a potentially life-threatening but preventable DOAC complication. Early recognition—particularly in elderly patients with comorbidities and polypharmacy—and urgent imaging for abdominal pain are crucial for improving clinical outcomes.

## Linked entities

- **Chemicals:** apixaban (PubChem CID 10182969), rivaroxaban (PubChem CID 6433119), dabigatran (PubChem CID 216210)
- **Diseases:** atrial fibrillation (MONDO:0004981), coronary heart disease (MONDO:0005010), malignancy (MONDO:0004992)

## Full-text entities

- **Diseases:** hypertension (MESH:D006973), splenic artery embolization (MESH:D013158), ASR (MESH:D013161), malignancy (MESH:D009369), coronary heart disease (MESH:D003327), atrial fibrillation (MESH:D001281), abdominal pain (MESH:D015746), infections (MESH:D007239)
- **Chemicals:** rivaroxaban (MESH:D000069552), apixaban (MESH:C522181), dabigatran (MESH:D000069604), DOAC (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13002362/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC13002362/full.md

## References

41 references — full list in the complete paper: https://tomesphere.com/paper/PMC13002362/full.md

---
Source: https://tomesphere.com/paper/PMC13002362